Literature DB >> 28396173

Contribution of alcohol use disorders on the burden of chronic hepatitis C in France, 2008-2013: A nationwide retrospective cohort study.

Michaël Schwarzinger1, Sylvain Baillot2, Yazdan Yazdanpanah3, Jürgen Rehm4, Vincent Mallet5.   

Abstract

BACKGROUND & AIMS: Hepatitis C virus (HCV) patients are at risk of alcohol use disorders (AUDs). We measured the contribution of AUDs on the burden of chronic HCV infection in French HCV patients.
METHODS: The hospital trajectory of 97,347 French HCV patients aged 18-65 in January 2008 were tracked and followed until in-hospital death or December 2013. Primary outcome was the frequency of liver-related complications. Secondary outcomes were the frequency of liver transplantation and otherwise cause-specific mortality. Adjusted odds ratios (OR), population attributable risks of AUDs and other cofactors of liver disease progression associated with HCV transmission were measured.
RESULTS: The 28,101 (28.9%) individuals with AUDs had the highest odds for liver-related complications (OR=7.19; 95% confidence interval [CI], 6.90 to 7.50), liver transplantation (OR=4.28; 95% CI, 3.80 to 4.82), and liver death (OR=6.20; 95% CI, 5.85 to 6.58). Alcohol rehabilitation and abstinence were associated with 60% (95% CI, 57% to 63%) and 78% (95% CI, 76% to 80%) reduction of liver-related complications, respectively. The attributable risk of AUDs was 71.8% (95% CI, 66.0 to 76.8) of 17,669 liver-related complications, 67.4% (95% CI, 61.6 to 72.4) of 1,599 liver transplantations, and 68.8% (95% CI, 63.4 to 73.5) of 6,677 liver deaths. The number of liver transplantations remained stable and the number of liver deaths increased, at a faster rate for individuals with AUDs, over the observational period.
CONCLUSION: In France, AUDs contributed to more than two-thirds of the burden of chronic HCV infection in young and middle-aged adults over 2008-2013. LAY
SUMMARY: This study tracked liver-related complications and mortality of all 97,347 young and middle-aged patients (18-65years old) discharged with chronic HCV infection from French hospitals over 2008-2013. About 30% patients were recorded with alcohol use disorders (AUDs) and had the highest odds for liver-related complications (i.e. decompensated cirrhosis and liver cancer). AUDs contributed to more than two-thirds of 1,599 liver transplantations and 6,677 liver deaths recorded in patients with chronic HCV infection over 2008-2013 in France. Alcohol rehabilitation and abstinence were associated with above a 50% risk reduction of liver-related complications. Promoting alcohol abstinence should receive high priority to reduce the burden of chronic HCV infection.
Copyright © 2017 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Alcohol use disorders; Burden of disease; Chronic hepatitis C; Cirrhosis; Disease progression; End-stage liver disease; Hepatocellular carcinoma; Mortality; Natural history; Prognosis

Mesh:

Year:  2017        PMID: 28396173     DOI: 10.1016/j.jhep.2017.03.031

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  14 in total

1.  Alcohol Consumption and Risk of Liver Cirrhosis: A Systematic Review and Meta-Analysis.

Authors:  Michael Roerecke; Afshin Vafaei; Omer S M Hasan; Bethany R Chrystoja; Marcus Cruz; Roy Lee; Manuela G Neuman; Jürgen Rehm
Journal:  Am J Gastroenterol       Date:  2019-10       Impact factor: 10.864

Review 2.  The oncologic burden of hepatitis C virus infection: A clinical perspective.

Authors:  Harrys A Torres; Terri Lynn Shigle; Nassim Hammoudi; James T Link; Felipe Samaniego; Ahmed Kaseb; Vincent Mallet
Journal:  CA Cancer J Clin       Date:  2017-07-06       Impact factor: 508.702

Review 3.  Global Burden of Disease and the Impact of Mental and Addictive Disorders.

Authors:  Jürgen Rehm; Kevin D Shield
Journal:  Curr Psychiatry Rep       Date:  2019-02-07       Impact factor: 5.285

4.  Estimating alcohol-attributable liver disease mortality: A comparison of methods.

Authors:  Adam Sherk; Marissa B Esser; Tim Stockwell; Timothy S Naimi
Journal:  Drug Alcohol Rev       Date:  2022-04-01

5.  Hepatitis C infection substantially reduces survival of alcohol-dependent patients.

Authors:  Roberto Muga; Arantza Sanvisens; Inmaculada Jarrin; Daniel Fuster; Ferran Bolao; Jordi Tor; Alvaro Muñoz
Journal:  Clin Epidemiol       Date:  2018-08-01       Impact factor: 4.790

6.  Trends in cause-specific mortality in HIV-hepatitis C coinfection following hepatitis C treatment scale-up.

Authors:  Nadine Kronfli; Sahir R Bhatnagar; Mark W Hull; Erica E M Moodie; Joseph Cox; Sharon Walmsley; John Gill; Curtis Cooper; Valérie Martel-Laferrière; Neora Pick; Marina B Klein
Journal:  AIDS       Date:  2019-05-01       Impact factor: 4.177

7.  Untreated alcohol use disorder in people who inject drugs (PWID) in France: a major barrier to HCV treatment uptake (the ANRS-FANTASIO study).

Authors:  Tangui Barré; Fabienne Marcellin; Vincent Di Beo; Jessica Delorme; Teresa Rojas Rojas; Philippe Mathurin; Camelia Protopopescu; François Bailly; Marion Coste; Nicolas Authier; Maria Patrizia Carrieri; Benjamin Rolland
Journal:  Addiction       Date:  2019-11-20       Impact factor: 6.526

8.  Global Burden of Alcohol Use Disorders and Alcohol Liver Disease.

Authors:  Jürgen Rehm; Kevin D Shield
Journal:  Biomedicines       Date:  2019-12-13

9.  Hepatitis C virus infection and risk of liver-related and non-liver-related deaths: a population-based cohort study in Naples, southern Italy.

Authors:  Pierluca Piselli; Diego Serraino; Mario Fusco; Enrico Girardi; Angelo Pirozzi; Federica Toffolutti; Claudia Cimaglia; Martina Taborelli
Journal:  BMC Infect Dis       Date:  2021-07-08       Impact factor: 3.090

10.  Alcohol use disorders and the risk of progression of liver disease in people with hepatitis C virus infection - a systematic review.

Authors:  Laura Llamosas-Falcón; Kevin D Shield; Maya Gelovany; Jakob Manthey; Jürgen Rehm
Journal:  Subst Abuse Treat Prev Policy       Date:  2020-06-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.